Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)

Not available.

[1]  A. Rosenwald,et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms , 2022, Leukemia.

[2]  L. Staudt,et al.  The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. , 2022, Blood.

[3]  C. Zent,et al.  Initial treatment of B‐cell prolymphocytic leukemia with ibrutinib , 2020, American journal of hematology.

[4]  O. Bernard,et al.  Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53. , 2019, Blood.

[5]  J. Byrd,et al.  iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. , 2018, Blood.

[6]  M. Damlaj,et al.  Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations , 2018, Leukemia & lymphoma.

[7]  Philipp W. Raess,et al.  Ibrutinib is an effective treatment for B‐cell prolymphocytic leukaemia , 2017, British journal of haematology.

[8]  A. Schuh,et al.  Idelalisib‐Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia , 2017, British journal of haematology.

[9]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[10]  C. Dearden Management of prolymphocytic leukemia. , 2015, Hematology. American Society of Hematology. Education Program.

[11]  G. Flandrin,et al.  A Multicentric Study of 41 Cases of B-Prolymphocytic Leukemia: Two Evolutive Forms: The Groupe Français d'Hématologie Cellulaire , 2001, Leukemia & lymphoma.

[12]  T. Crook,et al.  p53 abnormalities in B-cell prolymphocytic leukemia. , 1997, Blood.